RxDoctor Payments Data

Melanie Hungler

Medical · Cincinnati, OHNPI 1285878827

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 85.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $10,545 and has fallen 83.3% since, to $1,761 in 2024. Among medical clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,192in general payments, 2019–2025

Across 80 payments — averaging $202.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • Axonics, Inc.$2K
  • Astellas Pharma US Inc$204
  • Urovant Sciences Inc$95
  • Boston Scientific$28

What the payments were for

  • Consulting fees$1,60010%
  • Speaking & faculty fees$7,52446%
  • Travel & lodging$5,31633%
  • Food & beverage$1,58710%
  • Education$1651%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)48$13,784
Axonics, Inc.20$2,080
Astellas Pharma US Inc6$204
Urovant Sciences Inc5$95
Boston Scientific1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,192 in reported general payments places this provider in the 95th percentile of 547 medical providers in Ohio.

See all medical providers in Ohio

Medicare billing

Part B allowed, 2024
$50,837
Medicare patients
307
Services billed
784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron497$294,746
GemtesaVibegron240$173,412
Estradiol445$26,093
Mirabegron ErMirabegron55$20,887
PremarinEstrogens, Conjugated17$7,230
Trospium Chloride50$4,012
Trimethoprim24$2,225
Fosfomycin Tromethamine14$1,635
Cephalexin156$1,608
NitrofurantoinNitrofurantoin Macrocrystal19$627
CefuroximeCefuroxime Axetil25$419
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst54$407
Clobetasol Propionate17$338
Cefdinir20$192
Nystatin12$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$204$294,746497 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 547 medical providers in Ohio.

Other medical in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →